genengnews.com
Crohn's Disease Phage Therapy Neutralizes Inflammatory E. coli in Mouse Model
This study suggests a targeted phage can reduce inflammation driven by Crohn’s‑associated E. coli without wiping out the gut microbiome, and it may boost the effect of lower steroid doses. That could eventually mean treatments focused on harmful bacteria with fewer broad antibiotic or steroid side effects.
Researchers studying microbiome or phage therapies, clinicians interested in microbiome‑targeted IBD treatments, and patients curious about future precision microbial therapies.
What To Know
Researchers at McMaster University reported a preclinical study (Science Translational Medicine) showing bacteriophage therapy targeted to adherent‑invasive E. coli (AIEC) reduced inflammation in a mouse model of Crohn’s disease by suppressing a virulence switch (fimS/FimH) rather than eradicating the bacteria.
A phage named HER259 flipped the fimS promoter to an “off” orientation, lowering bacterial adhesion and colitis signs; stopping phage treatment allowed the promoter to revert and inflammation to return.
The team also tested combining the phage with low-dose budesonide and observed improved anti‑inflammatory effects compared with the low dose alone, suggesting the phage might allow lower steroid dosing.
The study used a defined gnotobiotic mouse model and a patient‑derived AIEC strain (NRG857c); results are preclinical and mechanistic rather than clinical evidence of safety or effectiveness in people.
Practical point: this work is an early, proof‑of‑concept preclinical report supporting targeted microbiome therapies (phage cocktails) as a complementary approach to current IBD treatments. It does not change clinical care yet and would require human trials to assess safety, durability, and real‑world benefit.
Researchers may find the genetic mechanism (fimS/FimH inversion) and the demonstrated synergy with budesonide useful for designing translational studies or phage‑based interventions.
Results are from a controlled mouse model with a single patient‑derived bacterial strain; effects reversed after stopping phage. Human safety, efficacy, dosing, durability, and delivery remain unknown and require clinical trials.
